Clinical Trials Logo

Clinical Trial Summary

Patients with traumatic spinal cord injury (tSCI) often suffer from spinal cord swelling inside the thecal sac, which contains the spinal cord and surrounding fluid, leading to increased pressure on the spinal cord tissue and decreased spinal cord blood flow at the site of injury. The combination of increased pressure and decreased blood flow causes vascular hypo-perfusion of the spinal cord and exacerbates the severity of injury. This is also referred to as secondary injury. Thus, knowledge of spinal cord hypo-perfusion would allow the treating physician to optimize the hemodynamic condition of patient with acute spinal cord injury and potentially improve functional outcome. We plan to use contrast-enhanced ultrasound (CEUS) to determine decrease of blood flow in the spinal cord at the site of injury, during the routine surgery that these patients require to decompress and stabilize their injured spine. This may help us to determine the efficacy of certain treatments in improving blood flow and patients suffering from tSCI.


Clinical Trial Description

Patients presenting to the Harborview Emergency room with acute traumatic spinal cord injury (tSCI) will be recruited to undergo contrast-enhanced ultrasound (CEUS) during routine surgery for decompression and stabilization of their injury.

Traumatic spinal cord injury (tSCI) develops in two phases. The primary injury is characterized by direct mechanical destruction of cells, nerve fibers and blood vessels. The secondary injury phase represents the downstream biological effects of the loss of blood flow in the injury center as well as significant hypoperfusion in the surrounding penumbral zone. This process is associated with cytotoxic spinal cord edema, which causes a rise of tissue pressure within the contused spinal cord. While experimental studies demonstrate that spinal cord tissue damage due to primary injury is often remarkably limited, the cascade of biochemical and molecular processes that comprise secondary injury often exacerbate and define the extent of injury to the patient.

Accordingly, two routinely performed clinical treatment strategies aim to mitigate the effects of secondary injury by improving the local tissue perfusion of the contused spinal cord. First, surgical decompression of the spinal cord is recommended within 24 hours after injury, as it may improve functional outcome. Second, trauma guidelines recommend maintenance of the mean arterial blood pressure at 85 - 90 Hg for the first 7 days after acute spinal cord injury.

Despite these interventions and a tremendous research effort to develop neuroprotective therapies targeting the hypoperfused "rescue-able" penumbral zone, there are no clinically efficacious techniques to improve functional outcome following tSCI. We believe that a lack of clinical biomarkers for hypoperfused "rescue-able" penumbral zone is a main road block for the development of novel therapeutic procedures and therapies. This motivates a search for a biomarker for tSCI that can guide surgical and critical care interventions. We seek to develop an ultrasound-based biomarker for tSCI that is sensitive to the underlying tissue pathology and predictive of clinical outcomes. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04056988
Study type Interventional
Source University of Washington
Contact Amy M Anderson, BSN RN
Phone 206-744-9364
Email amya9@uw.edu
Status Recruiting
Phase Phase 4
Start date July 31, 2018
Completion date December 31, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT04811235 - Optical Monitoring With Near-Infrared Spectroscopy for Spinal Cord Injury Trial N/A
Completed NCT00406016 - Acute Safety, Tolerability, Feasibility and Pharmacokinetics of Intrath. Administered ATI355 in Patients With Acute SCI Phase 1
Recruiting NCT05305118 - TSCS for Acute SCI N/A
Recruiting NCT05244408 - "SCRIBBLE" Spinal Cord Injury Blood Biomarker Longitudinal Evaluation
Recruiting NCT05731986 - Spinal Cord Transcutaneous Stimulation Effect on Blood Pressure in Acute Spinal Cord Injury (SCI) N/A
Recruiting NCT05426681 - Spinal Cord Injury Neuroprotection With Glyburide Phase 1
Recruiting NCT05745298 - The Use of Functional Electrical Stimulation in Conjunction With Respiratory Muscle Training to Improve Unaided Cough in Individuals With Acute Spinal Cord Injury N/A
Terminated NCT01750684 - AC105 in Patients With Acute Traumatic Spinal Cord Injury Phase 2
Recruiting NCT04475224 - Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury Phase 3
Enrolling by invitation NCT06030531 - Spasticity and Functional Recovery After SCI
Active, not recruiting NCT03935724 - Stem Cells in Spinal Cord Injury Phase 2/Phase 3
Recruiting NCT04054414 - PMZ-1620 (Sovateltide) in Patients of Acute Spinal Cord Injury Phase 2
Recruiting NCT06000592 - Safety, Feasibility, and Efficacy of TSCS on Stabilizing Blood Pressure for Acute Inpatients With SCI N/A
Completed NCT02325414 - Prevention of Bone Loss After Acute SCI by Zoledronic Acid Phase 2
Recruiting NCT02034669 - Transplantation of Autologous Adipose Derived Stem Cells (ADSCs) in Spinal Cord Injury Treatment Phase 1/Phase 2
Terminated NCT02232165 - Mean Arterial Blood Pressure Treatment for Acute Spinal Cord Injury N/A
Completed NCT02260713 - Autologous Bone Marrow Cell Transplantation in Persons With Acute Spinal Cord Injury- An Indian Pilot Study. Phase 1/Phase 2
Terminated NCT02524379 - Spinal Cord Injury Neuroprotection With Glyburide Phase 1/Phase 2
Not yet recruiting NCT06238492 - A Pilot RCT to Improve Cognitive Processing Speed in Acute SCI N/A
Completed NCT01502631 - Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects With Acute Spinal Cord Injury (ASCI) Phase 2